About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/18/2021.

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Clinicaltrials.gov identifier NCT02519452

Recruitment Status Recruiting

First Posted August 11, 2015

Last update posted January 3, 2020

Study Description

Brief summary:

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Drug: Daratumumab Subcutaneous (SC) Administration
    Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Phase: Phase 1
Detailed Description

This is an open-label (identity of assigned study drug will be known), multicenter, 3-part, Phase 1b dose escalation/expansion study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and antitumor activity of SC delivery of daratumumab to participant with relapsed or refractory multiple myeloma. Up to approximately 53 participants in part 1, 80 participants in part 2 and 15 participants per corticosteroid tapering cohort (up to approximately 30 participants total) in Part 3 will be enrolled. The purpose of Part 1 is to select an appropriate SC therapeutic dose for the mixture of daratumumab with rHuPH20 based on safety and pharmacokinetics. This dose, selected from part 1 will be the initial dose for the co-formulated daratumumab and rHuPH20 preparation to be evaluated in Part 2. The purpose of Part 2 is to evaluate the SC delivery of CF and confirm the dose level selected from Part 1 based on the pharmacokinetics, safety, and antitumor activity. The purpose of Part 3 is to evaluate the safety of Dara-CF 1800 mg SC delivery without pre-dose and post-dose corticosteroids. Participant's safety will be monitored throughout the study.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 108 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
  • Actual Study Start Date: October 2015
  • Estimated Primary Completion Date: December 2017
  • Actual Study Completion Date: November 2022
Arms and interventions
Arm Intervention/treatment
Experimental: Part 1: Cohort 1
Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
Drug: Daratumumab Subcutaneous (SC) Administration
Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Experimental: Part 1: Cohort 2
Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
Drug: Daratumumab Subcutaneous (SC) Administration
Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Experimental: Part 1: Cohort 3
Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
Drug: Daratumumab Subcutaneous (SC) Administration
Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Experimental: Part 2: Cohort 4
Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
Drug: Daratumumab Subcutaneous (SC) Administration
Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Experimental: Part 3: Dara-CF 1800 mg
Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
Drug: Daratumumab Subcutaneous (SC) Administration
Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.

Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Outcome Measures
  • Primary Outcome Measures: 1. Serum Trough Concentrations (Ctrough) of Daratumumab [ Time Frame: Up to cycle 3 (each cycle 28 days) Day 1 ]
    Ctrough: the concentration prior to study drug administration.
  • 2. Part 1, 2 and 3: Number of Participants with Adverse Events (AEs) and Serious AEs [ Time Frame: Screening up to follow-up (30 days after last dose administration) (Approximately up to 3.4 years) ]
    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
  • Secondary Outcome Measures: 1. Part 1, 2 and 3: Serum Concentration of Daratumumab and Recombinant Human Hyaluronidase (rHuPH20) (Plasma) Antibodies [ Time Frame: Approximately 2 years ]
    Serum levels of antibodies to Daratumumab and rHuPH20 for evaluation of potential immunogenicity.
  • 2. Part 1, 2 and 3: Percentage of Participants with Complete Response (CR) [ Time Frame: Approximately 2 years ]
    CR is Defined as the proportion of Participants achieving CR (including sCR) according to the International Myeloma Working Group (IMWG) criteria.
  • 3. Part 1, 2 and 3: Percentage of Participants With Overall Response Rate (ORR) [ Time Frame: Approximately 2 years ]
    Overall response rate is defined as the percentage of participants who achieve complete response, stringent complete response (sCR), partial response or very good partial response (VGPR) according to the International Myeloma Working Group criteria, during or after study treatment.
  • 4. Part 1, 2 and 3: Duration of Response (DR) [ Time Frame: Approximately 2 years ]
    The DR is time from date of initial documentation of response (PR or better) to date of first documented PD, as defined by IMWG criteria.
  • 5. Part 1, 2 and 3: Time to Response [ Time Frame: Approximately 2 years ]
    Time to response is defined as the time from the date of first dose of study treatment to the date of the first documentation of observed response (CR or PR or better than PR)
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Participants proven to have multiple myeloma (MM) diagnosis according to the
International Myeloma Working Group (IMWG) diagnostic criteria

- Measurable disease as defined by any of the following: (a) immunoglobulin (Ig) G
myeloma (serum monoclonal paraprotein [M-protein] level >=1.0 gram/deciliter [g/dL] or
urine M-protein level greater than or equal to (>=) 200 milligram[mg]/24 hours[hrs];
or (b) IgA, IgD, or IgE multiple myeloma (serum M-protein level >= 0.5 g/dL or urine
M-protein level >= 200 mg/24 hrs); or (c) light chain multiple myeloma (serum
immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa
lambda free light chain ratio)

- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
score of 0, 1, or 2

- Pretreatment clinical laboratory values must meet protocol-defined parameters during
the Screening phase

- Man, who is sexually active with a woman of child-bearing potential and has not had a
vasectomy, must agree to use a barrier method of birth control example (eg), either
condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap
(diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository,
and all men must also not donate sperm during the study and for 3 months after
receiving the final dose of study drug

- Relapsed or refractory disease. Relapse is defined as progression of disease after an
initial response to previous treatment, more than 60 days after cessation of
treatment. Refractory disease is defined as less than (=) 2 treatment lines of anti-myeloma
therapy. Prior lines of therapy must include a proteasome inhibitor (PI) (eg,
bortezomib, carfilzomib) and an immunomodulatory drug (IMiD) (example, thalidomide,
lenalidomide, pomalidomide) in any order during the course of treatment. Each prior
line of therapy may consist of one or more agents and may include induction,
hematopoietic stem cell transplantation, and/or maintenance therapy. Radiotherapy,
bisphosphonates, or a single short course of steroids is not considered a prior line
of therapy

Exclusion Criteria:

- Participant has received daratumumab or other anti-cluster of differentiation 38
(anti-CD38) therapies previously

- Participant has received anti-myeloma treatment within 2 weeks before Cycle 1 Day 1

- Participant has previously received an allogenic stem cell transplant; or participant
has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle
1 Day 1

- Participant has a history of malignancy (other than multiple myeloma) within 5 years
before Cycle 1 Day 1 (exceptions are squamous and basal cell carcinomas of the skin
and carcinoma in situ of the cervix, or malignancy that in the opinion of the
investigator, with concurrence with the sponsor's medical monitor, is considered cured
with minimal risk of recurrence)

- Participant is exhibiting clinical signs of meningeal involvement of multiple myeloma

Contacts and Locations
Contacts

Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

Locations
Show 15 Study Locations
Sponsors and Collaborators

Janssen Research & Development, LLC

Investigators

Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

More Information
  • Responsible Party: Janssen Research & Development, LLC
  • ClinicalTrials.gov Identifier: NCT02519452 History of Changes
  • Other Study ID Numbers: CR107838, 2015-001210-94, 54767414MMY1004
  • First Posted: August 11, 2015 Key Record Dates
  • Last Update Posted: January 3, 2020
  • Last Verified: January 2020
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Janssen Research & Development, LLC: Multiple Myeloma
    Daratumumab (JNJ-54767414)
    Recombinant Human Hyaluronidase
  • Additional relevant MeSH terms: Multiple Myeloma Neoplasms, Plasma Cell